5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
Key Takeaways
- Adherence to oral antineoplastic therapy commonly falls below 80% and both under-adherence and over-adherence cause harm, so adherence must be measured at every visit rather than assumed.
- Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort can reduce plasma concentrations of many oral kinase inhibitors enough to cause treatment failure.
- Proton pump inhibitors and H2 blockers substantially reduce absorption of pH-dependent agents such as erlotinib, dasatinib, and pazopanib, so acid suppression must be reviewed before starting these drugs.
- Food effects differ by agent: abiraterone must be taken on an empty stomach because food dramatically increases exposure, while capecitabine is taken within 30 minutes after a meal.
- Oral antineoplastics are hazardous drugs under USP <800>, so patients and caregivers require instruction on handling, storage, spill management, and disposal at home.
5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
Blueprint focus: ONCC Domain II.B — systemic therapy. Oral agents are systemic therapy delivered without a nurse present. That single fact changes everything about safety, and the exam tests it through adherence, drug interaction, food effect, and home-handling stems.
Why Oral Therapy Is Not Simply More Convenient
An infusion is witnessed, dose-verified, and administered by a nurse who can stop it. An oral kinase inhibitor is taken by a patient who may forget doses, double up after missing one, take it with grapefruit juice, add an over-the-counter omeprazole, or stop it entirely because of a rash they were too embarrassed to report. Every safeguard that the infusion suite provides has to be rebuilt through education, monitoring, and follow-up.
Adherence
Adherence to oral anticancer therapy is frequently reported below 80%, and it declines as therapy lengthens. Both directions are dangerous.
- Under-adherence causes subtherapeutic exposure and treatment failure. In chronic myeloid leukemia, adherence below 90% is associated with markedly lower rates of major molecular response — one of the clearest dose-response relationships in oncology.
- Over-adherence — taking a missed dose late, doubling up, or continuing through a toxicity that should have triggered a hold — causes avoidable grade 3 and 4 events.
Root causes and matched interventions
| Barrier | What it looks like | Intervention |
|---|---|---|
| Financial toxicity | Delayed refills, pill splitting, "I'm stretching it out" | Financial navigator, manufacturer patient assistance program, copay foundation grant, specialty pharmacy benefits check before the first fill |
| Unmanaged toxicity | Silent self-discontinuation after diarrhea or rash | Proactive prophylaxis, scheduled early check-in calls, explicit permission to call |
| Complexity | Multiple agents, cycled on-off schedules, food restrictions | Written calendar, pill organizer, alarms, simplified regimen where possible |
| Cognitive or sensory limits | Missed doses, confusion about the schedule | Caregiver involvement, large-print instructions, teach-back at every visit |
| Beliefs | "I feel fine so I stopped," or fear of dependence | Explain the mechanism and what happens if levels drop |
| Asymptomatic disease | Adjuvant endocrine therapy abandoned in year 2 | Frame absolute benefit; treat side effects rather than accepting discontinuation |
Measure adherence, do not ask a yes-or-no question. Use a normalizing, open prompt — "Most people miss doses sometimes. In the last week, how many did you miss?" — plus pill counts, refill records from the specialty pharmacy, and where available a validated instrument.
Drug and Food Interactions That Change Outcomes
CYP3A4
Most oral kinase inhibitors are CYP3A4 substrates.
- Strong inducers — rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort, enzalutamide — lower drug concentrations enough to cause treatment failure. Induction takes days to develop and days to reverse after stopping.
- Strong inhibitors — ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, and grapefruit and Seville orange juice — raise concentrations and cause toxicity.
Whenever a strong interacting drug is unavoidable, either the antineoplastic dose is adjusted according to labeling or a non-interacting alternative is substituted. Antifungal prophylaxis is a common real-world trigger for this problem.
Gastric pH
Several oral agents require an acidic stomach to dissolve. Proton pump inhibitors and H2 receptor antagonists can lower exposure substantially and cause failure.
- Markedly affected: erlotinib, dasatinib, pazopanib, nilotinib, gefitinib, capecitabine (with PPI, an association with worse outcomes has been reported).
- Mitigation: avoid PPIs where possible; if an H2 blocker is required, separate dosing by the interval specified in the label; antacids can often be separated by a few hours.
Food
| Agent | Requirement | Reason |
|---|---|---|
| Abiraterone acetate | Empty stomach — 1 hour before or 2 hours after food | Food can raise exposure severalfold, causing toxicity |
| Capecitabine | Within 30 minutes after a meal | Labeling and trial dosing were established with food |
| Erlotinib | 1 hour before or 2 hours after food | Food increases bioavailability substantially |
| Nilotinib | Avoid food 2 hours before and 1 hour after | Food raises exposure and QT risk |
| Lapatinib | Empty stomach | Food markedly raises exposure |
| All CYP3A4 substrates | Avoid grapefruit and Seville orange | Irreversible intestinal CYP3A4 inhibition |
QT prolongation
Nilotinib, vandetanib, and several other oral agents prolong the QT interval. Obtain a baseline electrocardiogram, correct potassium and magnesium, and review the full medication list for additive QT-prolonging drugs including ondansetron, methadone, azoles, and fluoroquinolones.
Safe Handling at Home
Oral antineoplastics remain hazardous drugs under USP <800> even outside the pharmacy. Teach patients and caregivers:
- Do not crush, split, chew, or open capsules unless the label explicitly permits it.
- Anyone other than the patient handling the tablets should wear disposable gloves.
- Wash hands before and after every dose.
- Store in the original labeled container, out of reach of children and pets, away from heat and humidity; do not put tablets in a shared weekly pill organizer unless a pharmacist confirms it is acceptable.
- People who are pregnant or breastfeeding should not handle the drug.
- Do not flush unused drug or put it in household trash — return it to a take-back program or the dispensing pharmacy.
- For a spill, use gloves, contain and clean with disposable materials, and dispose of them in a sealed bag.
- Body fluids may contain drug for several days after a dose; teach closing the toilet lid and flushing twice, and washing soiled linens separately.
Monitoring Cadence
Build the schedule around the specific agent's toxicity signature. A representative structure:
- Before the first dose: confirm indication and biomarker, reconcile all medications and supplements, check baseline organ function and electrocardiogram if indicated, verify insurance and out-of-pocket cost, and provide written and teach-back education.
- Days 7 to 14: telephone check-in for tolerability and early toxicity — this is when most patients silently stop.
- Every 2 to 4 weeks initially: targeted laboratory studies and toxicity grading (blood pressure and urine protein for VEGF inhibitors; thyroid function for several multikinase inhibitors; liver enzymes for many; complete blood count for PARP inhibitors; glucose and lipids for PI3K and mTOR inhibitors).
- Ongoing: adherence measurement at every visit, re-reconciliation of medications at every visit, and dose modification per label rather than patient-initiated interruption.
Toxicity is a reason to hold and dose-reduce, not a reason for the patient to quit. Say that sentence out loud to every patient starting an oral agent.
A patient with metastatic renal cell carcinoma has been taking pazopanib for 3 months with stable disease. She is started on omeprazole 40 mg daily by her primary care provider for reflux. What is the most important consequence the nurse practitioner should recognize?
A patient starting abiraterone acetate asks how to take it. Which instruction is correct?
A patient on imatinib for chronic myeloid leukemia reports at a routine visit that he 'sometimes' misses doses. What is the most appropriate assessment approach by the nurse practitioner?